We are pleased to announce that our open access journal Immunotherapy Advances has been given an inaugural impact factor of 4.1, establishing it as a leading publication in the field of immunology. The announcement came as part of Clarivate’s annual Journal Citation Report, and places Immunotherapy Advances in the second quartile for immunology journals.
This is a huge achievement for such a young journal, and we’d like to thank the editorial team, led by Founding Editor-in-Chief Professor Tim Elliott, for their incredible hard work, and everyone who has contributed to the journal’s continued success, including authors, readers, reviewers and editors.
In the rest of our publishing portfolio, our journal Clinical & Experimental Immunology achieved an impact factor of 3.4. Our youngest journal, Discovery Immunology, does not yet have an impact factor, but hit a major milestone in April when it was indexed in PubMed Central, one of the largest and most widely used repositories for biomedical and life sciences articles. Discovery Immunology also published its first ever Special Collection in April, on checkpoint molecules in cancer immunotherapy.
Impact factors are one of a range of measures that indicate the performance of a journal, and it is important to see them in their wider context. Below we set out some of the other key metrics and milestones for our three journals. Together, these demonstrate that we are continuing to achieve our goal of publishing high quality content that is timely and relevant to our research community.
We have also compiled a must-read collection of our most-viewed and most-cited articles from all three journals from the past 12 months, covering topics such as the contribution of B cells to immunometabolic dysfunction in obesity, predicting outcomes in small cell lung cancer and engineering of CAR-NK cells for cancer immunotherapy. All articles are open access and free to read.
Immunotherapy Advances
- Mean time to first decision: 48 days
- Mean time to final decision: 90 days
- 2,399 Altmetric mentions in the last year
- Yearly usage: 82,672 full-text downloads
Clinical & Experimental Immunology
- Mean time to first decision: 25 days
- Mean time to final decision: 43 days
- 10,990 Altmetric mentions in the last year
- Yearly usage: 834,560 full-text downloads
Discovery Immunology
- Mean time to first decision: 39 days
- Mean time to final decision: 79 days
- 3,544 Altmetric mentions in the last year
- Yearly usage: 37,616 full-text downloads
- Indexed in PubMed Central, Directory of Open Access Journals, Dimensions and Google Scholar
More information about our journals is available here. We offer a broad suite of additional benefits to authors, including a very rapid time to first decision, live Altmetric tracking on articles, no page or colour charges for members, integration with Publons, and the skills of a dedicated marketing team who promote articles to interested parties. BSI members also benefit from discounted publishing charges for all journals in the BSI family.
Profits from our journals are invested back into the BSI to benefit our members in the form of grants, travel awards, BSI Regional and Affinity Group meetings, our popular BSI Congress and other key initiatives. By submitting to one of our journals, you are supporting our work in all these areas and more.
You can share your papers online and keep up to date with news from the journals by following @CEIjournal, @IMTadvances and @discovimmunol on Twitter.